Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Winner
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Vertex Pharmaceuticals rose $3.06 (3.8%) to $84.70 on light volume. Throughout the day, 1,450,792 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,537,400 shares. The stock ranged in a price between $81.86-$84.78 after having opened the day at $82.05 as compared to the previous trading day's close of $81.64. Other companies within the Drugs industry that increased today were:
(
), up 16.8%,
(
), up 15.8%,
(
), up 15.7% and
Bacterin International Holdings
(
), up 14.9%.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.7 billion and is part of the health care sector. Shares are up 90.9% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.
TheStreet Ratings rates Vertex Pharmaceuticals as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.
- You can view the full Vertex Pharmaceuticals Ratings Report.
On the negative front,
(
), down 34.5%,
(
), down 28.0%,
(
), down 11.6% and
(
), down 8.1% , were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null